FIELD: medicine.
SUBSTANCE: invention relates to medicine, specifically to neurology and psychiatry, and concerns the treatment of cognitive disorders. To this end, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide is administered in an effective amount of 0.1-3.0 mg.
EFFECT: improvement of cognitive functions due to the administration of this drug in said low doses is provided by its long half-life in the human body.
13 cl, 3 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| TREATING COGNITIVE DISORDERS WITH (R)-7-CHLOR-N-(QUINUCLIDIN-3-YL) BENZO[b] THIOPHEN-2-CARBOXAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | 2009 |
|
RU2532327C2 |
| METHODS FOR COGNITIVE FUNCTION SUPPORT, TREATMENT OR IMPROVEMENT | 2013 |
|
RU2635522C2 |
| CRYSTALLINE FORM OF (R)-7-CHLORO-N-(QUINUCLIDIN-3-YL)BENZO[b]THIOPHENE-2-CARBOXAMIDE HYDROCHLORIDE MONOHYDRATE | 2011 |
|
RU2577334C2 |
| HETEROAROMATIC NMDA RECEPTOR MODULATORS AND THEIR USE | 2019 |
|
RU2800064C2 |
| ALKALOID DERIVATIVES OF AMINOESTERS AND THEREOF-INCLUDING DRUG COMPOSITIONS | 2011 |
|
RU2569846C2 |
| INDAZOLES, BENTOTHIAZOLES, BENZOISOTHIAZOLES, PRODUCTION AND USE THEREOF | 2003 |
|
RU2391341C2 |
| METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA WITH USING NEUROLEPTIC COMBINED THERAPY | 2007 |
|
RU2508096C2 |
| METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA WITH USING ATYPICAL NEUROLEPTIC COMBINED THERAPY | 2007 |
|
RU2508106C2 |
| BENZO[d] ISOXAZOLE-3 DAAO INHIBITORS | 2004 |
|
RU2384574C2 |
| 1,7-NAPHTHRIDINE-3-CARBOXAMIDE DERIVATIVES, USEFUL AS NEUROGENISIS AGENTS | 2014 |
|
RU2669943C2 |
